Buprenorphine/naloxone

Buprenorphine/naloxone (trade name Suboxone) is a combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor antagonist, and naloxone, a MOR silent antagonist, in a 4:1 ratio. It is used in the treatment of opioid dependence. The purpose of naloxone is to deter intravenous abuse; parenteral administration rapidly induces opioid withdrawal symptoms, while regular, intended use does not (as naloxone is minimally bioavailable with sublingual ingestion). In spite of the fact that the drug is intended to treat opioid dependence, it is still addictive.

Buprenorphine/naloxone

Buprenorphine/naloxone (trade name Suboxone) is a combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor antagonist, and naloxone, a MOR silent antagonist, in a 4:1 ratio. It is used in the treatment of opioid dependence. The purpose of naloxone is to deter intravenous abuse; parenteral administration rapidly induces opioid withdrawal symptoms, while regular, intended use does not (as naloxone is minimally bioavailable with sublingual ingestion). In spite of the fact that the drug is intended to treat opioid dependence, it is still addictive.